(Journal Article): The Diterpene Glycoside, Rebaudioside A, Does not Improve Glycemic Control or Affect Blood Pressure After Eight Weeks Treatment in the Goto-Kakizaki Rat
 
Dyrskog SEU, Jeppesen PB, Chen J, Christensen LP, Hermansen K (Department of Endocrinology and Metabolism C, Aarhus Sygehus THG, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus C, Denmark, stig.dyrskog(at)ki.au.dk )
 
IN: Rev Diabetic Stud 2005; 2(2):84-91
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: The plant, Stevia rebaudiana Bertoni (SrB), has been used for the treatment of diabetes in traditional medicine. Previously, we have demonstrated that long-term administration of the glycoside stevioside has insulinotropic, glucagonostatic, anti-hyperglycemic and blood pressure-lowering effects in type 2 diabetic animal models. The aim of this study was to elucidate if long-term administration of rebaudioside A, another glycoside isolated from the plant SrB, could improve glycemic control and lower blood pressure in an animal model of type 2 diabetes. We divided male Goto-Kakizaki (GK) rats into two groups which were fed a standard laboratory chow diet for eight weeks. The diet was supplemented with oral rebaudioside A (0.025 g/kg BW/day) in the experimental group. Blood glucose, weight, blood pressure and food intake were measured weekly. Animals were equipped with an intra-arterial catheter, and at week eight the conscious rats underwent an intra-arterial glucose tolerance test (IAGTT) (2.0 g/kg BW). During the IAGTT, the level of glucose, glucagon, and insulin responses did not differ significantly between the two groups. Fasting levels of glucose, glucagon, insulin or levels of blood lipids did not differ between the groups throughout the study period. We observed no effect on blood pressure or weight development. In conclusion, oral supplementation with rebaudioside A (0.025 g/kg BW/day) for eight weeks did not influence blood pressure or glycemic control in GK rats. Rebaudioside A failed to show the beneficial effects in diabetic animals previously demonstrated for stevioside.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988. 37:1595-1607.
2. World Health Organization. Definition, diagnosis and classi-fication of diabetes mellitus and its complications. Part 1: diag-nosis and classification of diabetes mellitus. Geneva: WHO De-partment of Noncommunicable Disease Surveillance 1999.
3. UK Prospective Diabetes Study (UKPDS) Group. Inten-sive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complica-tions in patients with type 2 diabetes (UKPDS 33). Lancet 1998. 352:837-853.
4. UK Prospective Diabetes Study Group. Tight blood pres-sure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998. 317:703-713.
5. Soejarto DD, Kinghorn AD, Farnsworth NR. Potential sweetening agents of plant origin. III. Organoleptic evaluation of Stevia leaf herbarium samples for sweetness. J Nat Prod 1982. 45:590-599.
6. Shibata H, Sawa Y, Oka T, Sonoke S, Kim KK, Yoshioka M. Steviol and steviol-glycoside: glucosyltransferase activities in Stevia rebaudiana Bertoni - purification and partial charac-terization. Arch Biochem Biophys 1995. 321:390-396.
7. Jeppesen PB, Gregersen S, Rolfsen SE, Jepsen M, Co-lombo M, Agger A, Xiao J, Kruhoffer M, Orntoft T, Her-mansen K. Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. Metabo-lism 2003. 52:372-378.
8. Dyrskog SEU, Jeppesen PB, Colombo M, Abudula R, Hermansen K. Preventive effects of a soy-based diet supple-mented with stevioside on the development of the metabolic syndrome and type 2 diabetes in ZDF rats. Metabolism 2005 In Press.
9. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Develop-ment of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 1988. 246:29-31.
10. Ostenson CG, Khan A, Abdel-Halim SM, Guenifi A, Suzuki K, Goto Y, Efendic S. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993. 36:3-8.
11. Movassat J, Saulnier C, Serradas P, Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia 1997. 40:916-925.
12. Metz SA, Meredith M, Vadakekalam J, Rabaglia ME, Kowluru A. A defect late in stimulus-secretion coupling im-pairs insulin secretion in Goto-Kakizaki diabetic rats. Diabetes 1999. 48:1754-1762.
13. Chan P, Xu DY, Liu JC, Chen YJ, Tomlinson B, Huang WP, Cheng JT. The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. Life Sci 1998. 63:1679-1684.
14. Chan P, Tomlinson B, Chen YJ, Liu JC, Hsieh MH, Cheng JT. A double-blind placebo-controlled study of the ef-fectiveness and tolerability of oral stevioside in human hyper-tension. Br J Clin Pharmacol 2000. 50:215-220.
15. Hsieh MH, Chan P, Sue YM, Liu JC, Liang TH, Huang TY, Tomlinson B, Chow MS, Kao PF, Chen YJ. Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study. Clin Ther 2003. 25:2797-2808.
16. Abudula R, Jeppesen PB, Rolfsen SE, Xiao J, Hermansen K. Rebaudioside A potently stimulates insulin secretion from isolated mouse islets: Studies on the dose-, glucose-, and cal-cium-dependency. Metabolism 2004. 53:1378-1381.
17. Gardana C, Simonetti P, Canzi E, Zanchi R, Pietta P. Me-tabolism of stevioside and rebaudioside A from Stevia rebaudi-ana extracts by human microflora. J Agric Food Chem 2003. 51:6618-6622.
18. Jeppesen PB, Gregersen S, Alstrup KK, Hermansen K. Stevioside induces antihyperglycemic, insulinotropic and gluca-gonostatic effects in vivo: Studies in diabetic Goto-Kakizaki (GK) rats. Phytomedicine 2002. 9:9-14.
19. Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 1978. 27:1691-1709.
20. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000. 85:4053-4059.
21. Hermansen K. Characterisation of the abnormal pancreatic D and A cell function in streptozotocin diabetic dogs: studies with D-glyceraldehyde, dihydroxyacetone, D-mannoheptulose, D-glucose, and L-arginine. Diabetologia 1981. 21:489-494.
22. Hermansen K, Schmitz O, Orskov H. Reversal of D- and A-cell insensitivity to glucose in alloxan diabetic dogs by treat-ment with the artificial beta-cell (Biostator). Diabetes 1985. 34:260-266.
23. Hsu YH, Liu JC, Kao PF, Lee CN, Chen YJ, Hsieh MH, Chan P. Antihypertensive effect of stevioside in different strains of hypertensive rats. Zhonghua Yi Xue Za Zhi (Taipei) 2002. 65:1-6.
24. Chang SS, Cook JM. Stability studies of stevioside and re-baudioside A in carbonated beverages. J Agric Food Chem 1983. 31:409-412.
25. Toyoda K, Matsui H, Shoda T, Uneyama C, Takada K, Takahashi M. Assessment of the carcinogenicity of stevioside in F344 rats. Food Chem Toxicol 1997. 35:597-603.
26. Hutapea AM, Toskulkao C, Buddhasukh D, Wilairat P, Glinsukon T. Digestion of stevioside, a natrual sweetener, by various digestive enzymes. J Clin Biochem Nutr 1997. 23:177-186.
27. Wingard RE, Jr. , Brown JP, Enderlin FE, Dale JA, Hale RL, Seitz CT. Intestinal degradation and absorption of the glycosidic sweeteners stevioside and rebaudioside A. Experientia 1980. 36:519-520.
28. Koyama E, Kitazawa K, Ohori Y, Izawa O, Kakegawa K, Fujino A, Ui M. In vitro metabolism of the glycosidic sweet-eners, stevia mixture and enzymatically modified stevia in hu-man intestinal microflora. Food Chem Toxicol 2003. 41:359-374.
29. Geuns JM, Augustijns P, Mols R, Buyse JG, Driessen B. Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol. Food Chem Toxicol 2003. 41:1599-1607.
30. Koyama E, Sakai N, Ohori Y, Kitazawa K, Izawa O, Kakegawa K, Fujino A, Ui M. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. Food Chem Toxicol 2003. 41:875-883.
31. Simonetti P, Gardana C, Bramati L, Pietta P. Bioavailability of stevioside from Stevia Rebaudiana in human volunteers: preliminary report. In: Geuns JM, Buyse JG, Eds. The Safety of Stevioside. Euprint ed. 2004.6, pp. 51-62.